Melbourne, Australia – 3 March 2014 – Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that it has been granted patents in the USA and Canada relating to the Company’s proprietary novel anti-fibrotic compounds.
The US patent is entitled “Halogenated Analogues of Anti-Fibrotic Agents” and the Canadian patent is entitled “Therapeutic Compounds”. Both have been granted composition of matter claims.
Prof. Darren Kelly, CEO of Fibrotech commented:
“We are poised to announce Phase I results for our lead product so the granting of these patents is timely and will help us greatly in ongoing partnering discussions.”
Fibrotech entered the clinic in 2013 with its lead product FT011 for diabetic nephropathy. Kidney failure in diabetes occurs as a result of kidney fibrosis (scarring). This fibrosis is in turn due to the long term damage from excessive sugar levels in the blood. The results from a Phase I trial of FT011 will shortly be released.
Professor Darren Kelly, CEO of Fibrotech will be attending BIOEurope Spring in Turin on 10th and 11th of March and will be happy to meet with interested journalists and other parties there.
Notes to Editors
About Fibrotech Therapeutics Pty Ltd
Fibrotech is an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis (tissue scarring). The Company develops novel anti-fibrotic drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as chronic kidney disease, chronic heart failure, pulmonary fibrosis and arthritis. Fibrotech’s lead product FT011 is an antifibrotic to prevent the tissue fibrosis associated with diabetic nephropathy and is currently undergoing safety testing in a Phase I clinical trial. Diabetic nephropathy is the leading cause of end-stage renal disease, a severe medical condition that can only be managed with dialysis or kidney transplantation. There are several products in preclinical development selected from over 150 analogues, many of which are novel chemical entities and are markedly improved antifibrotic agents. Fibrotech was founded in 2006 and is located in Melbourne Australia.
Further information on Fibrotech can be found at www.fibrotech.com.au
Issued for and on behalf of Fibrotech Therapeutics.
To contact the Fibrotech team at Instinctif Partners, email InstinctifLifeSciencesAustralia@instinctif.com
Sue CharlesManaging Partner